Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.
The Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, a patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application".
This new patent increases the number of issued patents related to the Company's buccal drug delivery platform technologies to 161. A total of 102 patent applications remain pending.
"We are pleased that we continue to establish the inventiveness of the Company's buccal delivery system as there has been relatively little progress over the years in reaching the target of safe and effective oral formulations for macromolecules, including peptides and proteins", stated Rose C. Perri, the Company's Chief Operating Officer. "We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialized with a pipeline of viable applications that will open up other marketplaces for the Company".
Breakthrough gene therapy method utilizes bird retrotransposon for safe gene insertion